Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOG), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Alpha Cognition Inc. (NASDAQ: ACOG) is a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, particularly Alzheimer’s disease and cognitive impairment associated with mild traumatic brain injury (mTBI). The Alpha Cognition news feed on Stock Titan aggregates company announcements, clinical updates, and capital markets disclosures so readers can follow how its Alzheimer’s and neuroscience programs progress over time.
News for ACOG frequently centers on the commercialization of ZUNVEYL, an FDA-approved new-generation acetylcholinesterase inhibitor for mild to moderate Alzheimer’s dementia in adults. Company releases describe launch momentum in the U.S. long-term care channel, including growth in pharmacy orders, expansion of the prescriber base, and increasing penetration into nursing homes. Updates also cover payer coverage developments, such as additional pharmacy benefit manager contracts, and the company’s efforts to deepen relationships with long-term care facilities.
Investors and healthcare observers will also find coverage of clinical and real-world evidence studies involving ZUNVEYL and ALPHA-1062, including planned and ongoing studies in Alzheimer’s disease patients in long-term care settings and research on cognitive impairment following traumatic brain injury. Alpha Cognition regularly reports on scientific presentations at meetings like the American Society of Consultant Pharmacists and the Neuroscience Education Institute, where it shares data on cholinesterase inhibitors, treatment persistence, and patient outcomes.
In addition, the ACOG news stream includes financing transactions, such as public offerings and at-the-market programs, licensing agreements for ZUNVEYL in Asia, and SEC-reportable events like changes in auditors or stock incentive plans. By reviewing this page, readers can track how Alpha Cognition’s commercial execution, clinical data, and corporate actions evolve, all in one consolidated news hub.
Alpha Cognition (NASDAQ: ACOG) announced CEO Michael McFadden will participate in three investor conferences in May 2026: Market Movers Investor Summit (May 5), H.C. Wainwright BioConnect at Nasdaq (May 19), and Craig Hallum Institutional Investor Conference (May 28). Select presentations will be webcast and archived on the company investor relations website.
Alpha Cognition (Nasdaq: ACOG) appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of finance, strategy, and operations experience, including CFO roles at Radius Health and 9 Meters, and Biogen P&L responsibility for >$1 billion across 30 countries. The company said her expertise will support the commercial launch of ZUNVEYL and ongoing development of its sublingual program. Alpha Cognition also announced that founding director Len Mertz will not seek re-election after guiding the company to an FDA-approved product.
Alpha Cognition (NASDAQ: ACOG) announced inducement grants of nonstatutory stock options to a new non-executive employee under its 2026 Inducement Grant Plan dated April 14, 2026. The grant covers 20,000 options with an exercise price of $6.49 per share.
Options vest over three years: 25% at one year, then monthly over the next 24 months, and are subject to the plan and option agreement terms.
Alpha Cognition (NASDAQ: ACOG) announced the USPTO issued U.S. Patent No. 12,589,099 on March 31, 2026 for ALPHA-1062 to treat confirmed and suspected traumatic brain injury (TBI). The patent extends protection through 2045 and complements existing patents covering ALPHA-1062 and ZUNVEYL.
The company highlights a potential addressable market of $14 billion for TBI and positions the patent as strengthening long-term asset value and commercial opportunities for its pipeline.
Alpha Cognition (NASDAQ: ACOG) saw accelerating commercial traction for ZUNVEYL at the end of FY25. 4Q25 net product revenue reached $2.5M and FY25 revenue was $10.2M, including $6.8M from ZUNVEYL. Bottles dispensed rose 62% q/q to 4,941, with December at a record 1,859.
Adoption metrics show 729 ordering homes and 865 prescribers, with repeat orders at 82% and repeat writers at 69%. The company ended FY25 with $66.0M cash, which management says funds commercialization into 2027 and supports expected sequential sales growth in 2026.
Alpha Cognition (NASDAQ:ACOG) reported fiscal 2025 results and operational progress for ZUNVEYL on March 26, 2026. Q4 net product revenue was approximately $2.5M; full-year revenue was $10.2M, including $6.8M product and $3.4M licensing. Cash totaled $66.0M, supporting a ~two-year runway after a $40M October 2025 raise.
Commercial momentum: Q4 bottles dispensed 4,941 (+62% QoQ), December 1,859; Q4 prescribers +50% QoQ; two national PBM contracts in place. Ongoing and planned studies include BEACON, CONVERGE, and RESOLVE; additional patent issued and sublingual program advancing to clinic in 2026.
Alpha Cognition (Nasdaq: ACOG) will report fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026 at 4:30 p.m. ET, after market close.
Management will host a conference call and live webcast following the release; replay details and dial-in numbers will be available. Materials will be posted in the company's investor News section.
Alpha Cognition (Nasdaq: ACOG) will present new clinical data on ZUNVEYL (benzgalantamine) at two upcoming conferences: the American Association of Geriatric Psychiatrists (April 16-20, 2026) and the Neuroscience Education Institute Spring Congress (May 1-3, 2026).
Multiple poster presentations will report on nicotinic receptor modulation, acetylcholinesterase inhibitor persistence, delayed nursing home placement, and psychotropic medication use in Alzheimer’s disease and related dementias.
Alpha Cognition (NASDAQ: ACOG) enrolled the first patient in BEACON, a Phase 4 real-world effectiveness study evaluating ZUNVEYL in long-term care (LTC) residents with Alzheimer’s disease.
BEACON is a post-approval study planned for ~200 patients across multiple sites, collecting cognition, neuropsychiatric, safety, and tolerability data; topline results are expected in Q4 2026.
Alpha Cognition (NASDAQ: ACOG) announced the USPTO has issued U.S. Patent No. 12,551,491 covering dosage regimens for benzgalantamine, which the company says supports oral dosing methods for treating mild to moderate Alzheimer’s disease. The patent is expected to protect ZUNVEYL in the U.S. through July 2045.
Alpha Cognition said the method-of-use claims reinforce its patent portfolio, bolster ZUNVEYL’s long-term differentiation, and advance the company’s intellectual property strategy for benzgalantamine administration.